Savara Inc
NASDAQ:SVRA
Savara Inc
Cash & Cash Equivalents
Savara Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Cash & Cash Equivalents
$15.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-8%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$5.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$10B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$12B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$17.9B
|
CAGR 3-Years
84%
|
CAGR 5-Years
62%
|
CAGR 10-Years
39%
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
15.1m
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Cash & Cash Equivalents amounts to 15.1m USD.
What is Savara Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-8%
Over the last year, the Cash & Cash Equivalents growth was -43%. The average annual Cash & Cash Equivalents growth rates for Savara Inc have been -24% over the past three years , -21% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet